March 7, 2014 | Just days after the announcement of his new company, Human Longevity, Craig Venter sat down with Eric Topol, director of the Scripps Translational Science Institute to discuss the future of genomic medicine. Venter spoke about if he'd considered exomes instead of WGS (no, the goal is predictive medicine), competition with Google's Calico (press loves it, but he doesn't care who wins), government funding (had to be a for profit company because investments are easier to get than grants), and more. Next Gen Seek has Storified the session, and Reuters covered the session.